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REVIEW
The therapeutic potential of sialylated Fc domains of human IgG
Richard J. Pleass
Department of Tropical Disease Biology, Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, UK
ABSTRACT
Pathogens frequently use multivalent binding to sialic acid to infect cells or to modulate immunity 
through interactions with human sialic acid-binding immunoglobulin-type lectins (Siglecs). Molecules 
that interfere with these interactions could be of interest as diagnostics, anti-infectives or as immune 
modulators. This review describes the development of molecular scaffolds based on the crystallizable 
fragment (Fc) region of immunoglobulin (Ig) G that deliver high-avidity binding to innate immune 
receptors, including sialic acid-dependent receptors. The ways in which the sialylated Fc may be engi-
neered as immune modulators that mimic the anti-inflammatory properties of intravenous polyclonal Ig 
or as blockers of sialic-acid-dependent infectivity by viruses are also discussed.
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Introduction
Sialic acid-containing molecules play important roles in many 
fundamental immunological and pathological processes via 
carbohydrate–protein interactions that occur during the devel-
opment of the immune system and during immune responses 
to pathogens.1,2 Examples include the regulation of fluid-phase 
innate immunity and modulation of leukocyte trafficking via 
sialylated selectin ligands.3 Two members of the sialic acid 
family (Neu5Ac and Neu5Gc) commonly occur as the terminal 
constituents of carbohydrate chains and are attached through 
post-translational modifications to glycoproteins at N- and 
O-linked attachment sites within the protein (Figure 1).
Immunoglobulin G (IgG) molecules, which are critical 
components of the immune system, have structures and func-
tions that can be radically affected by changes to the glycan 
backbone (Figure 1). Approximately 30–50 different glycan 
structures, with and without sialic acid, can be attached to 
N-linked attachment sites in IgG specified by the asparagine- 
X-threonine/serine (Asn-X-Thr/Ser) sequence, where X can be 
any amino acid other than proline.5 Within IgG, one such 
conserved site at Asn-297 in the Fc is always occupied with 
a glycan, while 15–20% of variably occupied N-linked sites can 
also arise spontaneously in the antigen-binding fragments 
(Fabs) during antibody development (Figure 1).6
The oligosaccharides attached to Asn-297 are essential for 
the binding and activation of FcRs and complement compo-
nent C1q as this functionality is abrogated or severely curtailed 
by enzymatic removal or site-directed mutagenesis of the Asn- 
X-Thr/Ser attachment site.7–9 Numerous IgG-Fc crystal struc-
tures show Asn-297 glycans to be integral to the Fc structure, 
where they are buried within the internal cavity enclosed by the 
two CH2 domains (Figure 1). This buried location makes it 
extremely difficult for the glycans to interact directly with 
glycan receptors but allows them to modify the overall con-
formation of the Fc peptide backbone,10 thereby affecting the 
interactions with FcRs and complement component C1q 
(Figure 1).
More detailed studies into the types of sugars involved in 
this functionality have shown enhanced FcRIIIA binding and 
antibody-dependent cell-mediated cytotoxicity (ADCC) of 
IgG1 in the absence of fucose;11,12 enhanced FcRIIIA binding 
but rapid clearance from the circulation of IgG1 enriched for 
oligomannose structures;13–15 and improved solubility, anti- 
inflammatory activity, thermal stability, and circulatory half- 
life of terminally sialylated glycans from IgG1.16–20 The sialyla-
tion of IgG Fc domains also impairs complement-dependent 
cytotoxicity.21 The presence of Asn-297 terminal capping sialic 
acid may also prevent clearance of IgG by the asialoglycopro-
tein receptor that binds to terminal galactose residues of 
N-glycans.22 Therefore, glycosylation, including terminal sia-
lylation, is important for antibody function. Consequently, this 
review will explore how IgG, and in particular the Fc, may be 
engineered to enhance interactions with sialic acid-binding 
receptors that play a crucial role in the anti-inflammatory 
properties of IgG or as therapeutic blockers of sialic-acid 
dependent infectivity by viruses.
Sialic acid and the anti-inflammatory properties of IgG
Intravenously administered IgG (IVIG) is a highly successful 
biologic approved for treating several autoimmune diseases 
(ADs), including idiopathic thrombocytopenic purpura (ITP), 
chronic inflammatory demyelinating polyneuropathy, 
myasthenia gravis, and other neurological illnesses.23 As 
~70% of the global supply (worth ~$8.9 billion in 2017) of 
IVIG is now used to treat ADs, it can be unavailable to other 
patients who desperately need it, in particular individuals with 
primary immune deficiency where IVIG is used as replacement 
therapy.24 Worldwide consumption of IVIG has increased over 
400-fold since 1980 and currently >100 tons are consumed per 
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annum. Global supplies of IVIG are critically limited, meaning 
that patients with an urgent need for the drug can have 
restricted access to it (https://www.alliedmarketresearch.com/ 
intravenous-immunoglobulin-IVIG-market).
The therapeutic utility of IVIG has substantial limitations, 
including dependence on human donors for its manufacture, 
and from the fact that less than 5% of injected IVIG is ther-
apeutically active, leading to a requirement for high doses (1– 
2 g/kg) when used in treating most ADs. Consequently, IVIG is 
expensive and adverse events due to excessive protein loading 
are not uncommon.23,24 There is thus an urgent clinical need to 
develop cheaper, safer, and more effective alternatives to IVIG 
that are effective at lower dosages, although efforts have been 
hindered by a lack of understanding of its likely pleiotropic 
mechanisms of action.25
Many therapeutic modes of action have been attributed to 
IVIG. It is beyond the scope of this review to cover all such 
mechanisms in detail, but several excellent review articles on 
the topic are available.26–29 Here, the focus is on the mechan-
isms in which sialic acid engineering approaches have been 
undertaken.
Changes in antibody sialylation have been associated with 
the evolution of autoimmune and inflammatory diseases, 
including rheumatoid arthritis and juvenile idiopathic arthritis, 
which are associated with decreased levels of IgG sialylation, 
and particularly of the pathogenic IgG found in inflamed joints 
of patients.30,31 Levels of sialylated IgG increase during preg-
nancy and correlate with remission from arthritis in pregnant 
women.32 Furthermore, pathogenic anti-proteinase three auto-
antibodies are less sialylated in patients with active Wegener’s 
vasculitis.33 The observation that increased levels of endogen-
ous IgG sialylation increased the likelihood of successful treat-
ment of Kawasaki disease in patients treated with IVIG, and 
that patients with severe Guillain-Barré syndrome also show 
lower levels of IgG sialylation despite IVIG treatment have 
stimulated research into converting such observations into 
therapies.34,35 These clinical observations have been substan-
tiated in multiple mouse models of arthritis and other ADs 
where approximately 10-fold improvements in the severity of 
disease are seen with sialic-acid enriched IVIG.20,35 
Approximately 30-fold improvements over IVIG in anti- 
inflammatory activity can also be demonstrated using sialy-
lated Fc, recombinant antibodies or hypersialylated IVIG pre-
parations (e.g., M254).19,20,36,37 Developed by Momenta 
Pharmaceuticals, Inc., M254 was shown to be well tolerated 
in healthy subjects,38 and is now being investigated in patients 
with ITP (Phase 1/2 study NCT03866577).
Sialic acid engineering approaches to the Fc glycans
The controlling influence of Asn-297 oligosaccharides on Fc- 
mediated effector functions of antibodies has driven experi-
mental approaches to modify them, either through glycoengi-
neering/chemoenzymatic means,19,39 by mutagenesis 
programs on the Fc protein backbone that disrupt the protein- 
Asn-297-carbohydrate interface,40 or by expression in glycosi-
dase-adapted transgenic cell lines.41 For example, the marketed 
humanized antibody mogamulizumab, used to treat lym-
phoma, is manufactured in Chinese hamster ovary (CHO) 
cells in which the α(1-6)-fucosyltransferase (FUT8) gene is 
Figure 1. The crystal structure of human IgG1. X-ray crystal-structure coordinates were taken from the Protein Data Bank entry 1HZH.4 One heavy chain is shown in cyan, 
the other in magenta, and the N-linked oligosaccharides attached to Asn-297 in IgG1 are shown in pink. A simplified view of the relevant N-linked sugars that may be 
found at Asn-297 is shown in cartoon format with the terminal N-acetylneuraminic acid (Neu5Ac) shown as pink diamonds. The Fab arms are shown in gray. *Although 
terminal sialylation on complex N-glycans can happen via either an α2,3-linkage or α2,6-linkage as depicted in the figure, sialic acids on human serum IgG Fc are almost 
exclusively α2,6-linked. Recombinant IgG or Fc expressed in Chinese hamster ovary (CHO) cells, however, have sialic acids attached through α2,3-linkages because of the 
lack of the α2,6-sialyltransferase gene.
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removed, resulting in an afucosylated IgG1 with enhanced 
FcRIIIA-dependent tumor cell killing by ADCC.42 Although 
similar approaches have yielded enhanced sialylation of IgG, 
with zero to moderate improvements in binding to 
FcRs,19,40,43,44 these have not led to significant enhancements 
in binding to inhibitory Siglecs that are important in control-
ling unwanted inflammation,44–46 a finding that others have 
attributed to the buried location of the Asn-297-attached gly-
can within the Fc.10,47
Approaches to enhance the sialylation of IgG have to date 
focussed on modifications to the known preexisting N-linked 
glycosylation sites.19,40,48,49 My colleagues and I took an alter-
native approach to enhancing the sialic acid content of the Fc 
of IgG1 by adding the 18 amino acid tailpiece from IgM that 
contains an N-linked glycosylation site at Asn-563 to the 
C-terminus of the IgG1 Fc,50–53 and into which a cysteine-to- 
alanine substitution at Cys-575 may be introduced to prevent 
covalent multimerization (Figure 2). A further N-linked glyco-
sylation site can also be introduced, if desired, to the 
N terminus at position Asn-221.50 By inserting or removing 
in different combinations the Asn-221, Asn-297 and Asn-563 
glycosylation sites, a panel of variably glycosylated Fc mono-
mers can be generated.51 As a result, tetravalent, octavalent, 
and dodecavalent Fc monomers can be made with respect to 
the attached terminal sialic acid (Figure 2a). Both non-covalent 
or covalently bonded higher ordered multimers, e.g., with 
possible sialic acid valences up to 72 for the hexamers depicted 
in Figure 2b, can then be generated from the basic Fc unit by 
the addition or removal of cysteines (Cys-309/Cys-575), either 
alone or in combination with the tailpiece Asn-563 glycan, that 
radically increase the available oligosaccharide combining sites 
(Figure 2b). 47,51,53
Hexamers of the IgG1-Fc with no additional 
N-glycosylation sites introduced, other than the glycan found 
at Asn-297, are currently in clinical development as they have 
been shown to block cytotoxicity and pathological changes in 
experimental in vitro and rat models of neuromyelitis optica 
through mechanisms that involve interference with comple-
ment activation.56–58 However, potential drawbacks to the 
clinical use of hexamers include their large size (~350 kDa) 
and presence of multiple disulfide bonds that may combine to 
limit manufacture to scale by commercially available cell lines.
We therefore created a large panel of cysteine- and 
N-glycan-adapted mutants from the parent hexamer, including 
molecules with additional N-link attachment sites at Asn-221 
and Asn-563.50–52 Because the Asn-297 glycan is largely buried 
within the Fc,10,47 (Figure 1) the location of Asn-221 and Asn- 
563 at the tips of the Fc imparts alternative functional attributes 
to these molecules (Figure 2a). 51 Five combinations of glyco-
sylation and cysteine substitution mutants that formed either 
monomers or multimers and possessed different binding char-
acteristics for FcRs, C- and I-type lectins and complement 
components were shortlisted.55 As sialylation of IgG-Fc 
domains is believed to be important for the anti- 
Figure 2. A model of sialylated Fc. (A) The Asn-221, Asn-297, and Asn-563 containing Fc (D221N/C309L/C575A) containing at least eight sialic acid (colored green) 
combining sites was modeled on the IgG1 structure (pdb 1HZH).4 The N-linked glycan was attached using glycan entry 8388 (http://www.glycosciences.de) in GlyProt54 
using the following torsion angles of 180, 340, 160, 280 and 90, 180, 160, 280 for the Asn-221 and Asn-563 attached sugars, respectively. The Asn-297 glycans are 
superimposed from the 1HZH IgG1 structure on which the dimer co-ordinates and final model was aligned using PyMol version 1.20. (B) Multimers of the monomeric Fc 
unit shown in (A) (hexamer shown) can be generated through mutagenesis approaches as previously described.47,50,52,53,55
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inflammatory effects of IVIG,35,59,60 molecules containing sim-
ple mono-antennary sialylation and larger more complex tri- 
and tetra-antennary sialylation were selected for study in an ex 
vivo model of antibody-mediated demyelination of the nervous 
system.55 The relative abundance of complex sialylated struc-
tures on mutants that did not protect (e.g., D221N/C309L/ 
N297A/C575A), compared to the paucity of sialylated struc-
tures on mutants that did protect, argues against a direct role 
for sialic acid in this particular model of neurological disease.55 
This observation is supported by studies in a number of AD 
models that have shown the protective effects of IVIG to be 
largely independent of sialylation or interactions with DC- 
SIGN.44,61 However, the sialylation state of the Fc may become 
critical in vivo, especially for neurological diseases, where the 
influx and efflux of IgG through the blood–brain barrier has 
been shown to be dependent on glycan- and sialic acid- 
dependent mechanisms.62,63
Additional heterogeneity to the glycan profiles with dra-
matic functional consequences can occur by expressing the 
molecules in either CHO or human endothelial kidney 
(HEK) cell lines.51 Unlike CHO cells, HEK cells have an active 
α2,6-sialyltransferase. As such, CHO-derived Fcs can only be 
sialylated through α2,3 linkages, whereas both α2,3 and α2,6 
linkages can be found on molecules expressed by HEK cells.51 
The potential clinical and therapeutic applications of these 
variably glycosylated Fc molecules are discussed below.
Modulation of Siglecs
Through their capacity to activate or inhibit immune 
responses, Siglecs have become attractive therapeutic 
targets.64–66 Humans possess 14 different Siglecs that bind 
sialic acid. Siglec-3 (also known as CD33) belongs to a group 
of related Siglecs that include Siglec-5,-6, −7, −8, −9, −10, 
−11.64 These inhibitory Siglecs carry immunoreceptor tyro-
sine-based inhibitory motifs (ITIMs) and/or ITIM-like motifs 
in their cytoplasmic domains that lead to signaling cascades 
that suppress the activity of immune cells leading to anti- 
inflammatory effects.67 Consequently, synthetic sialylated 
ligands, such as sialo-polymers, sialo-nanoparticles, sialylated 
RNAs, and sialo-liposomes, that can bind Siglecs are being 
developed.68–72 Other promising strategies for enhancing sia-
lylation use exogenous sialyl-transferases and donors, as well as 
blockade of glycosphingolipid biosynthesis.49,73
Many of these, including anti-CD33 monoclonal antibodies 
(mAbs) in clinical development, will interact with Siglecs in 
trans (Figure 3a), meaning that these synthetic ligands engage 
cell-surface Siglecs from the surrounding medium. Cross- 
linking CD33 on monocytes via antibodies induces pro- 
inflammatory effects, while cis binding of sialic acids to CD33 
represses IL-1β production by monocytes.75 Consequently, cis 
ligands for Siglecs that reside on the same cell membrane may 
be superior at maintaining inhibitory signals that increase the 
threshold for immune activation, and this may make them 
Figure 3. A model for the known interaction of sialylated Fc with Siglec-3 (CD33). (A) Potential sialylated scaffolds can target Siglecs in trans as depicted with anti-CD33 
mAbs or, (B) may cross-link Siglecs in cis as illustrated with sialylated Fc-fragments disabled for receptor binding to FcRs or C1q. (C) The C-terminal tailpiece glycans on 
the D221N/C309L/C575A structure shown in B (rotated 90°) docked into the known sialic acid-binding site of Siglec-3 (pdb, 6D49)74 using PyMol. One Fc heavy chain is 
shown in cyan, the other in magenta, and the N-linked oligosaccharides attached to the Fc are shown in their respective heavy-chain color. Two Siglec-3 N-terminal 
V domains are shown in yellow and salmon, respectively. The critical sialic acid-binding residues on Siglec-3 are enlarged in the circle, and discussed in the 
accompanying text, are shown in blue spheres interacting with the Asn-563 glycan backbone in cyan with terminal α2,3-linked sialic acids shown in green. (D) The 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































useful for anti-inflammatory therapy (Figure 3b). 67 Indeed, the 
depletion of cis Siglec ligands has been shown to increase the 
activity of both macrophages and microglia, and other studies 
have shown that the metabolic blockade of sialic acid renders 
phagocytes more prone to activation.67 Based on these obser-
vations, it is anticipated that small high-affinity multivalent 
sialic acid-ligands that are better at diffusing in and around 
membranes than larger synthetic sialic acid-liganded molecules 
would have less potential for trans-mediated binding. 
Compared to other sialylated scaffolds that may bind CD33 
in trans, e.g., antibodies, the sialylated Fc offers a number of 
attractive biophysical and therapeutic properties over chemi-
cally generated non-natural sialoside polymerization platforms 
(or even mAbs) for targeting Siglecs therapeutically in cis 
(Table 1).
We previously identified sialylated Fc candidates that bound 
CD33 yet showed minimal binding to Fc-receptors and com-
plement C1q.52 Siglec-3 is a validated target for acute myeloid 
leukemia, and versions of the receptor that cannot bind sialic 
acid correlate with susceptibility to Alzheimer’s disease.77,78 
Siglec-3 is also believed to be a common determinant of SARS- 
CoV-2 infection and severe respiratory distress syndrome 
mediated by cytokine storms.79
The Fc glycovariant D221N/C309L/C575A (shown in 
Figure 3c) bound CD33 when expressed by CHO-K1 but did 
not bind when expressed by HEK cells,52 suggesting that 
α2,3-linked sialosides are more important to CD33 binding as 
these are the only linkages attached by CHO cells. This is in line 
with CD33 having been reported to have a preference for α2,3- 
over α2,6-linked sialosides with a reported weak binding affi-
nity (EC50 = 2–5 mM).80 The corresponding mutant in which 
the hinge Asn-221 glycan was removed (C309L/C575A) is still 
capable of binding CD33 indicating that the primary CD33 
interacting glycans are located in the tailpiece at Asn-563 
(Figure 3c).
We therefore generated a model of D221N/C309L/C575A to 
which sialic acid was attached via α2,3-linkages to Asn-221 and 
Asn-563 (Figure 3c,d). These structures were then docked to 
the known sialoside binding site of CD33 (Figure 3c,d). Only 
one arm of the α2,3-sialylated tailpiece glycan could be accom-
modated within the shallow-binding pocket of the N-terminal 
V-set domain, with contacts made to the conserved Arg-119, 
Lys-126, Lys-130, and Phe-117 residues seen in the ligand- 
bound crystal (Figure 3c,d). Superimposition of the docked 
CD33 V-set domain with the other available crystal structures 
from Siglecs-1, 2, and 4, offered possible models to explain why 
this Fc glycovariant could also bind these receptors.51,52
We have yet to test binding of D221N/C309L/C575A, or 
indeed any of the other Fc mutants, to Siglecs-6, −7, −8 and −9 
largely because the commercially available Siglecs are direct 
fusions to the Fc. In a similar vein, we were unable to test 
binding to human Siglec-5 because we observed significant 
direct binding of Fab′2 detecting reagents to this receptor. The 
Fab′2-mediated binding to Siglec-5 was dependent on glycans, 
because treatment of the Fab′2 detecting reagent with neura-
minidase abrogated binding to Siglec-5.50,81 Siglec-5 may 
therefore be a target for Fab glycans that have also been 
associated with the anti-inflammatory activity of IVIG.6 As 
the described Fc mutants can contain many different sialylated 
structures,51,55 it will be important to precisely define Siglec 
binding to avoid potential off-target effects given the ubiqui-
tous expression of Siglecs on many different types of cells and 
tissues. Greater homogeneity (leading to enhanced specificity) 
to the type of sialylated structures attached to Asn-221, Asn- 
297, or Asn-563 may be imparted using enzymatic and/or 
click-chemistry approaches described by others.19,49
The D221N/C309L/C575A glycovariant may target CD33 in 
cis (Figure 3b), as the negatively charged N-terminal hinge- 
located Asn-221 glycans may discourage interactions with FcRs 
in trans that are more likely to occur with mAb approaches 
(Figure 3a). Furthermore, the considerably smaller size of the 
Fc offers other advantages, including superior penetrability of, 
for example, the blood–brain barrier or of hard tumors, that 
may be more difficult to achieve with mAbs, sialo-polymers, 
sialo-nanoparticles, or sialo-liposomes (Table 1). Therefore, 
approaches that combine antibody Fc and glyco-mimetic tar-
geting of Siglecs may offer advantages over mAb-only or gly-
comimetic-only strategies.
Sialic acid receptors of viruses
Sialic acids linked to glycoproteins and gangliosides are used by 
many viruses as a receptor for cell entry.82,83 Such viruses 
include significant human and animal pathogens, including 
influenza, parainfluenza, corona, mumps, noro, rota, adeno, 
and DNA tumor viruses.82 Attachment to sialic acid is 
mediated through receptor-binding proteins that are exposed 
at the surface of non-enveloped viruses. Some of these viruses 
are also equipped with neuraminidase or a sialyl-O-acetyl- 
esterase, which are receptor-destroying enzymes that can pro-
mote virus release from infected cells and neutralize sialic acid- 
containing soluble proteins that interfere with cell surface 
binding of the virus.84
One example is the influenza virus, which assembles hun-
dreds of hemagglutinin (HA) trimers on its surface to recog-
nize sialic acid-galactose linkages on target tissue.84,85 The 
monovalent interaction between HA and a typical sialylated 
lactosamine ligand is weak (mM range), but multivalency- 
enhanced interactions allow firmer adhesion at low 
concentration.86,87 Molecules that bind HA with high avidity 
may therefore be useful as diagnostics or anti-infective 
medicines.68,86,87 Consequently, many studies have explored 
multivalent scaffolds to present sialic acid to HA with the aim 
of blocking the interaction between virus and host receptors.86– 
93 Many different scaffolds have been used to chemically attach 
sialic acid, including antibodies, DNA, fullerenes, graphene, 
polyacrylamide, quantum dots, magnets, silver and gold nano-
particles, although biocompatibility and potential toxicological 
liabilities of all of these remain and none have progressed to 
approval for use in humans.76,94 Controlling the spatial distri-
bution and number of ligand-bearing units in these oligomers 
can also be sub-optimal and/or ill-defined, leading to reduced 
binding or promiscuous binding to other sialic acid receptors 
(Table 1). The lack of target specificity can lead to faster in vivo 
clearance rates and may also explain reported toxicities for 
many polymeric inhibitors.95,96
This has driven the search for smaller, rationally designed 
sialylated scaffolds. Using a rigid self-assembled peptide 
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nucleic acid complex, it has recently been shown that smaller 
bivalent displays of the natural sialyl-LacNAc ligand (50–68 Å 
between each sugar) are more effective at binding a single HA 
trimer and inhibiting hemagglutination by virus than longer 
scaffolds with sialic acid residues separated by distances >100 Å 
that may allow for inter-HA bridging, which may also be 
desirable.86,87 Electron micrograph analyses have shown the 
average distance between two adjacent HA trimers to be 
101.7±0.6 Å.86 (Figure 4b)
We have previously shown that a sialylated Fc construct 
(molecule D221N/C309L/N297A/C575A) generated in CHO- 
K1 cells could potently inhibit binding to HA and blocked 
hemagglutination by influenza A and B viruses.51,52 Although 
D221N/C309L/N297A/C575 does not bind FcRs or C1q, other 
Fc mutants that partially blocked influenza B and retained FcR 
and C1q binding were also made, e.g., D221N/N563A/ 
C575A.51 The lack of binding to FcRs or complement may be 
therapeutically useful, as no interference with neutralizing 
antibodies raised by influenza vaccines would be expected. 
Through additional interactions with Siglecs, the sialylated Fc 
can mimic the known anti-inflammatory pathways of IgG that 
can protect patients from overt inflammatory responses, e.g., 
cytokine storms that can kill.99,100
In contrast to CD33, binding to HA is driven by the hinge- 
attached glycan located at Asn-221, as its removal in the C309L/ 
N297A/C575A mutant abrogated binding.52 The lower 
hemagglutination inhibition assay (HIA) activity seen by the 
C309L/N297A/C575A mutant, in which the tailpiece Asn-563 
glycan is retained, was surprising as the tailpiece Asn-563 glycan 
can be required for the anti-influenza virus activity of human 
anti-HIV virus IgA.101 All Fc constructs tested to date in the 
HIA assay contain adapted human IgM tails, but the findings of 
Maurer et al.,101 suggest that different binding to HA may be 
acquired using the IgA backbone in which the tailpiece differs at 
seven of the 18 amino acids to the tailpiece found in IgM.
The narrowest and widest distances achievable between the 
sialic acid residues in our modeled Fc are ~30–70 Å and 110– 
150 Å, respectively (Figure 2a), suggesting that the sialic acid- 
adapted Fc may allow both intra-HA and inter-HA binding 
(Figure 4). The hinge and tailpiece regions of the Fc are known 
to be highly flexible and the attached sialic acids may therefore 
reach more widely spaced HA trimers on the surface of more 
than one virus particle.102 We previously observed that this 
octa-sialylated Fc was consistently more effective at inhibiting 
influenza B than influenza A viruses (EC50, ~30 nM vs. 
~250 nM in HIA).51 To investigate possible structural explana-
tions for these observations, we evaluated the molecular inter-
actions of the D221N/C309L/N297A/C575A sialylated Fc with 
known crystal structures of HA from both influenza A and 
B viruses (Figure 4).
We docked one neuraminic acid unit from each of the two 
hinges into the cleft specifying the receptor-binding domain 
Figure 4. A model for the known interaction of the sialylated Fc with influenza hemagglutinin. (A) The N-terminal hinge domain Asn-221 attached glycans, one from 
each Fc (shown in magenta and cyan) docked into two of the three available sialic acid-binding sites found in the influenza A hemagglutinin trimer shown in yellow 
(pdb, 3LZG).97 Blue spheres show amino acids in the RBD of HA known to interact with sialic acid (green) and discussed in the text. (B) The location of glycans at each 
end of the Fc may also facilitate inter-HA binding. Close-up of the boxed binding site shown for HA from influenza A. (C) The sialylated Fc docked into the RBD from 
influenza B (pdb, 3BT6).98 Coloring of critical residues as for panels A and B.
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(RBD) of HA from influenza A (Figure 4a), with one face of the 
pyranose ring toward the bottom of the depression, and the 
other face exposed to solution as in published structures.97,103,104 
All the relevant ring substituents of α-NeuAc can interact with 
known key residues including, Trp-153, Asp-190, Thr-136, Lys- 
155, Lys-221, and Glu-226 within the RBD (Figure 4a). In this 
model, adjacent N-acetylgalactosamine and 
N-acetylglucosamine can also form independent interactions 
with the peptide backbone of HA (Figure 4b).
Influenza B diverged from influenza A approximately 
4,000 years ago105 and we were interested in understanding 
how the octa-sialylated Fc inhibited hemagglutination by the 
B virus more effectively than the A virus. The influenza B RBD 
in the globular head of HA is noticeably longer and wider, 
allowing the sialic acid on the Fc to be more comfortably 
accommodated within the RBD.98 (Figure 4c)
Sialic acid is also the substrate for influenza neuraminidase 
(NA). We do not yet know if sialylated Fcs are susceptible to 
cleavage by influenza NA. Although a decoy for NA may be 
a therapeutically attractive strategy,106 we have not observed 
a direct decay in the HIA after prolonged incubation. This 
suggests that the high specific avidity of these molecules for 
HA may reduce their susceptibility to NA, a hypothesis that fits 
with the relatively low efficiency of NA (kcat = 30–155s−1), 
together with the asymmetric distribution of NA in relation 
to HA on the surface of filamentous influenza viruses.76,84,107
To be useful, in compounds when administered intranasally 
or as an aerosol, the sialylated Fc needs to outcompete the 
sialylated mucins that viruses use, through ratchet-like interac-
tions with HA and NA, to migrate to the underlying respiratory 
epithelium.84 Of the 15 known human mucins in the human 
lung, only MUC5 has been shown to give protection from 
influenza.108,109 Most sialic acid found on human mucins are 
O-glycosylated, and where N-linked attachments do occur, these 
are mostly sialylated via α2,6-linkages.109 Thus, we were sur-
prised that none of the Fc leads inhibited influenza A or influ-
enza B agglutination of human O+ erythrocytes when 
manufactured by HEK cells, which attach the more human 
type α2,6-linked sialic acid.51 The apparent importance of 
α2,3-linked N-glycans to the inhibition of both influenza A and 
B by the CHO-K1 Fc mutants indicates that viruses can evolve 
away from inhibition by mucus, whose predominant O-linked 
glycans are mostly α2,6-linked.109,110 Our working hypothesis is 
that HEK-expressed sialylated Fc may inhibit influenza viruses 
that circulate in human populations or that are propagated in cell 
lines that attach more human-like α2,6-linked sialic acid. The 
findings suggest that sialylated Fcs may also be useful blockers of 
coronavirus S glycoproteins that mediate attachment to oligosac-
charide receptors, such as MERS-CoV, which also binds 
α2,3-linked, and to a lesser extent, α2,6-linked sialic acids.82,111
Recent reports have demonstrated that the current H3N2 
viruses no longer have a strict specificity toward human-type 
receptors, which may result in loss of binding by the sialylated 
Fc to these viruses.112 It has become clear that H3N2 viruses 
maintain human-type specificity but have evolved a preference 
for a subset of sialylated receptors with branched glycans and 
extended poly-N-acetyl-lactosamine (poly-LacNAc) chains113 
that are not attached to any of the inhibitory Fcs expressed in 
either CHO or HEK cells.51 Because this specificity is also 
shared with the 2009 pandemic H1N1, enhanced Fc blockers 
may potentially be created by manufacturing these molecules 
in human respiratory cell lines where such sialic acid attach-
ments are known to occur.114 Alternatively, enzymatic and/or 
click-chemistry approaches may be used to build the required 
glycan structure onto the Asn-221 and Asn-563 acceptor sites 
as documented previously for IgG.19,49
In summary, multivalent sialylated IgG Fcs offer many 
advantages over existing approaches to deliver high-avidity 
blocking or triggering of sialic acid-dependent receptors, such 
as Siglecs (Table 1). The proven abilities of the Fc to be 
intravenously injected16 and of Fc-fusions to be delivered 
directly into the eye115 or as an aerosol to the respiratory 
tract116 are particularly noteworthy. As the binding epitope 
for all hemagglutinins is sialic acid and is determined by the 
host, these ligands are less prone to viral escape by genetic drift 
compared to mAbs and, unlike mAbs, are more readily man-
ufactured and improvable through click-chemistry approaches 
to the glycan backbone as a consequence of introducing addi-
tional N-linked glycosylation at exposed sites in the Fc.
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